Login / Signup

Response to COVID-19 vaccination in patients on cancer therapy: Analysis in a SARS-CoV-2-naïve population.

George CavicAndrew A AlmonteSarah M HicksTeresa NeemanJo-Wai WangSue BrewPhilip Y ChoiIan CockburnElizabeth E GardinerDesmond YipAude M FahrerYada Kanjanapan
Published in: Asia-Pacific journal of clinical oncology (2024)
Most patients and all controls became seropositive after two vaccine doses. Antibody concentrations and seropositivity showed a decrease between 1 and 3 months post vaccination, highlighting need for booster vaccinations. SARS-CoV-2 infection amplifies S-RBD antibody responses; however, cannot be adequately identified using nucleocapsid serology. This underlines the value of our COVID-naïve population in studying vaccine immunogenicity.
Keyphrases